Intended Use
Loss of heterozygosity (LOH) of 1p can be detected in about 67% of oligodendroglial tumors and has also been identified in neuroblastomas and other tumor entities. Co-deletion of 1p/19q is a well-accepted prognostic biomarker in neuro-oncology. Patients suffering from anaplastic oligodendroglioma harboring 1p/19q deletion generally have a good prognosis. Co-deletion of 1p/19q also has predictive character, the molecular status of 1p/19q is relevant for therapy decisions. The presence of polysomy in oligodendroglia tumors with codeletion of 1p/19q predicts early recurrence and short survival in patients with 1p/19q codeleted tumors.
Patient Preparation
- Sample collection: FFPE Tissue Block (or) Non-diluted bone marrow aspirate (or) Peripheral Blood collected in a sodium heparinized Vacutainer.
- Specimen preparation: Do not freeze or expose to extreme temperatures.
- FFPE Tissue Block: Formalin fix (10 percent neutral buffered formalin) and paraffin-embed tissue (3–4-micron thick sections in positively charged/silanized slides). Fixative duration: 6-48 hours.
- Bone Marrow: Transfer 3 mL bone marrow to a Green (Sodium Heparin). (Min: 1 mL)
- Whole Blood: Transport 5 mL whole blood. (Min: 2 mL)
- Storage/Transport Temperature: Room temperature.
- Unacceptable Conditions: Frozen specimens. Clotted specimens.
- Remarks:
- Stability: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Methodology
Fluorescence in situ Hybridization (FISH)
Sample received to report Turnaround time (TAT)
3 working days
Reference Interval
————-
Interpretive Data
The most recent WHO classification of Tumours of Hematopoietic and Lymphoid Tissues (Revised 5th edition) is used for interpretation criteria for evaluation.
Resources
- Additional Technical Information
- Test Request Form
- Additional Technical Information
- Test Request Form
Sample Reports
- Enhanced Report
- See report